LXRX Relative Valuation
LXRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LXRX is overvalued; if below, it's undervalued.
Historical Valuation
Lexicon Pharmaceuticals Inc (LXRX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.62. The fair price of Lexicon Pharmaceuticals Inc (LXRX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.42
Fair
-5.16
PE
1Y
3Y
5Y
Trailing
Forward
-4.81
EV/EBITDA
Lexicon Pharmaceuticals Inc. (LXRX) has a current EV/EBITDA of -4.81. The 5-year average EV/EBITDA is -5.16. The thresholds are as follows: Strongly Undervalued below -18.57, Undervalued between -18.57 and -11.87, Fairly Valued between 1.55 and -11.87, Overvalued between 1.55 and 8.25, and Strongly Overvalued above 8.25. The current Forward EV/EBITDA of -4.81 falls within the Historic Trend Line -Fairly Valued range.
-4.43
EV/EBIT
Lexicon Pharmaceuticals Inc. (LXRX) has a current EV/EBIT of -4.43. The 5-year average EV/EBIT is -3.99. The thresholds are as follows: Strongly Undervalued below -11.65, Undervalued between -11.65 and -7.82, Fairly Valued between -0.15 and -7.82, Overvalued between -0.15 and 3.68, and Strongly Overvalued above 3.68. The current Forward EV/EBIT of -4.43 falls within the Historic Trend Line -Fairly Valued range.
25.07
PS
Lexicon Pharmaceuticals Inc. (LXRX) has a current PS of 25.07. The 5-year average PS is 600.26. The thresholds are as follows: Strongly Undervalued below -2198.89, Undervalued between -2198.89 and -799.31, Fairly Valued between 1999.84 and -799.31, Overvalued between 1999.84 and 3399.41, and Strongly Overvalued above 3399.41. The current Forward PS of 25.07 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Lexicon Pharmaceuticals Inc. (LXRX) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.24. The thresholds are as follows: Strongly Undervalued below -40.84, Undervalued between -40.84 and -23.54, Fairly Valued between 11.06 and -23.54, Overvalued between 11.06 and 28.35, and Strongly Overvalued above 28.35. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Lexicon Pharmaceuticals Inc. (LXRX) has a current P/FCF of 0.00. The 5-year average P/FCF is 5.01. The thresholds are as follows: Strongly Undervalued below -62.09, Undervalued between -62.09 and -28.54, Fairly Valued between 38.56 and -28.54, Overvalued between 38.56 and 72.11, and Strongly Overvalued above 72.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Lexicon Pharmaceuticals Inc (LXRX) has a current Price-to-Book (P/B) ratio of 4.29. Compared to its 3-year average P/B ratio of 3.01 , the current P/B ratio is approximately 42.85% higher. Relative to its 5-year average P/B ratio of 3.62, the current P/B ratio is about 18.55% higher. Lexicon Pharmaceuticals Inc (LXRX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -39.59%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -32.09% , the current FCF yield is about -100.00% lower.
4.29
P/B
Median3y
3.01
Median5y
3.62
-14.27
FCF Yield
Median3y
-39.59
Median5y
-32.09
Competitors Valuation Multiple
The average P/S ratio for LXRX's competitors is 0.00, providing a benchmark for relative valuation. Lexicon Pharmaceuticals Inc Corp (LXRX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 710.40%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LXRX increased by 92.28% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 1.75M to 14.18M.
The secondary factor is the Margin Expansion, contributed -97.57%to the performance.
Overall, the performance of LXRX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Lexicon Pharmaceuticals Inc (LXRX) currently overvalued or undervalued?
What is Lexicon Pharmaceuticals Inc (LXRX) fair value?
How does LXRX's valuation metrics compare to the industry average?
What is the current P/B ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Dec 05 2025?
What is the current FCF Yield for Lexicon Pharmaceuticals Inc (LXRX) as of Dec 05 2025?
What is the current Forward P/E ratio for Lexicon Pharmaceuticals Inc (LXRX) as of Dec 05 2025?